62004-35-7

62004-35-7 structure

Name: LFM-A13
Chemical Name: LFM-A13,2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide
CAS Number: 62004-35-7
Molecular Formula: C₁₁H₈Br₂N₂O₂
Molecular Weight: 360.00
Catalog: Signaling Pathways Cell Cycle/DNA Damage Polo-like Kinase (PLK)
Create Date: 2016-12-29 10:47:00
Modify Date: 2024-01-20 23:48:03
LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]

Name	LFM-A13,2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide
Synonyms	2-Butenamide, 2-cyano-N-(2,5-dibromophenyl)-3-hydroxy-, (2Z)- a-Cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl)propenamide (2Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide trans-4,5-didehydro-neral dehydrocitral trans-dehydroneral 2,4,6-Octatrienal,3,7-dimethyl (2Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide

Description	LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK Signaling Pathways >> Cell Cycle/DNA Damage >> Polo-like Kinase (PLK) Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Btk
Target	Plx1:10 μM (IC50) PLK3:61 μM (IC50) BRK:267 μM (IC50) BMX:281 μM (IC50) FYN:240 μM (IC50) Met:215 μM (IC50) Btk:2.5 μM (IC50)
References	[1]. Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999 Apr 2;274(14):9587-99. [2]. van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385(5):409-13. [3]. Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2007 Jan 15;15(2):800-14. [4]. Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2018 Jun;36(3):388-395.